RxDoctor Payments Data

Chad Watts, MD

Adult Reconstructive Orthopaedic Surgery · Reno, NVNPI 1124314935

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $57,948 of the $77,820 with a category attached, or 74.5%. Smith+Nephew accounts for 92.7% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $42,880, 7.3 times the $5,851 reported in 2019.

$77,820in general payments, 2019–2025

Across 98 payments — averaging $794.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$72K
  • Restor3d, Inc.$5K
  • Stryker$660
  • Onkos Surgical, Inc.$105
  • World Class Technology Corporation$80
$3,148in ownership & investment interests, 2019–2025

Across 1 payment — averaging $3148.12 each. An ownership or investment interest held by the physician or an immediate family member.

  • Restor3d, Inc.$3K

What the payments were for

  • Consulting fees$57,94874%
  • Travel & lodging$16,48121%
  • Food & beverage$3,3914%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$682,363
Medicare patients
883
Services billed
5,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate43$724
Meloxicam238$550
Oxycodone Hcl35$234
Tramadol Hcl78$217
Amoxicillin77$126
Mupirocin25$109
Gabapentin26$96
Ondansetron OdtOndansetron14$96
Ondansetron Hcl14$38

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →